After the FDA Approval: Next Steps for Penpulimab in NPC
Aditya Shreenivas, MD, MS, discusses the clinical trial that led to the FDA approval of penpulimab in nasopharyngeal carcinoma.
Related Articles
Determining Cytoreductive Therapy Initiation: Evidence-Based Decision Points
Panelists discuss how the decision to initiate cytoreductive therapy in polycythemia vera (PV) is driven by high-risk features such as age over 60 and thrombotic…
Improving Health Equity: The First Transcontinental HIFU Procedure in Prostate Cancer
Ruben Olivares, MD, discusses the important implications of the first transcontinental robot-assisted focal therapy procedure for prostate cancer.
SC Pembrolizumab in NSCLC May Boost Patient Experience, Efficiency
Enriqueta Felip, MD, PhD, discusses how results from the phase 3 3475A-D77 trial evaluating subcutaneous pembrolizumab vs intravenous pembrolizumab, plus chemotherapy, for the treatment of…
AI-Powered Pathology Tools May Boost Precision Oncology
Stuart J. Schnitt, MD, discussed artificial intelligence enhancements roadblocks, and potential integration for cancer diagnostics with Targeted Oncology.
Panitumumab Boosts Survival in RAS/BRAF Wild-Type Locally Advanced Colon Cancer
Panitumumab combined with FOLFOX improves survival and reduces recurrence in RAS/BRAF wild-type locally advanced colon cancer.
Academic Perspectives and Key Considerations for Optimal Patient Care in cGVHD
A panelist discusses how successful management of chronic graft-vs-host disease (cGVHD) requires a multifaceted approach that combines prompt recognition, strategic intervention, and comprehensive supportive care…
Talazoparib/Enzalutamide Combination Prolongs Health Status and Quality of Life in mCRPC
Talazoparib plus enzalutamide significantly delayed the deterioration of global health status and quality of life in patients with mCRPC in the TALAPRO-2 study.
Orca-T Improves GVHD-Free Survival in Advanced Hematologic Malignancies
Amandeep Salhotra, MD, discusses data from the phase 3 Precision-T trial of Orca-T in patients with advanced hematologic malignancies.
Improved Outcomes With Transplant After Cladribine-Based Therapy in AML
Transplantation improves survival after cladribine-based therapy for patients with relapsed/refractory acute myeloid leukemia, per phase 2 trial findings.
Tarhini Breaks Down RELATIVITY-047 Survival Benefits and PFS2
During a live event, Ahmad Tarhini, MD, PhD, discussed the RELATIVITY-047 trial of nivolumab/relatlimab vs nivolumab alone in advanced melanoma.